IJSRP, Volume 8, Issue 5, May 2018 Edition [ISSN 2250-3153]
Eng. Waseem Bakheet Al-hawari; Eng. Ghassan Khater Alighzawi; Eng. Thair Akram Haddad; RN. Maher Khaled Bani-Yaseen; Eng. Mohammad Jamil Alhusban
A trial fibrillation is the most common sustained heart abnormality and play a crucial role in the prevalenceof morbidity and mortality. AF is related proportionally with aging and structural heart diseases such as hypertension, valvular heart disease or coronary artery disease. According to the World Health Organization (W.H.O), around 2% of people with age less than 65 have experienced the AF before, while the ratio increases sharply to reach 9% of people older than 65 years. For example,in United States of America the estimation shows that between (2.7 to 6) million people have atrial fibrillation. A study published in 2014 by Chugh and his team focused on the global distribution ratio of atrial fibrillation, showed that about 0.5 % of population around the world producing more than 33.5 million people around the world suffering from atrial fibrillation, the study predicted that in 2050 the number of person in USA who are suffering from atrial fibrillation will increase rapidly to reach 8 million.